Table of Contents

HK J Paediatr (New Series)
Vol 21. No. 1, 2016

HK J Paediatr (New Series) 2016;21:7-13

Original Article

Different Outcome with Different Aetiologies: The Prognosis Follow-up in 13 Infants with Burst-suppression Pattern

J Shen, SS Mao, ZF Yuan, YL Yu, ZZ Xia, F Gao


Abstract

Purpose: Burst-suppression is an electroencephalogram (EEG) pattern which can be caused by various aetiologies and with poor outcome. The aim of our study was to investigate the outcome of children with burst-suppression pattern on EEG accompanied with different aetiologies. Methods: There were 13 infants with burst-suppression pattern on EEG included in our study, eight cases were diagnosed as Ohtahara syndrome (OS), while other four cases were diagnosed as early myoclonic encephalopathy (EME) and one case was diagnosed as hypoxic-ischaemic encephalopathy (HIE). All patients were followed up for eight months to two years, including the clinical evaluation and the EEG registration every three months. Findings: OS and EME were two common diseases associated with burst-suppression pattern. Partial seizure was the most common seizure type in all burst-suppression pattern patients. And spasm was more often in OS patients while myoclonia was common in EME patients. The period of burst-suppression pattern on EEG was several months in all OS and EME patients, while which was less than two weeks in one HIE patient. The HIE patient had the best out come while the EME patients had the worst outcome in these patients. The prognosis in OS patients is in between the HIE patient and EME patients. Conclusions: The outcome of development and cognition were poor in most of burst-suppression patients. The prognosis was different with different aetiologies. The aetiology and the rapidity of EEG improvement af fected the outcome.

Keyword : Burst-suppression; Early myoclonic encephalopathy; Neurologic outcome; Ohtahara syndrome


Abstract in Chinese

 
 

©2018 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.